Helix BioPharma Corp.

Helix BioPharma Corp. is a Canadian biopharmaceutical company headquartered in Toronto and focused on the discovery and early clinical development of cancer medicines. Its principal research interests include solid tumors and hematological malignancies, particularly cancers that are difficult to treat with established approaches. The company has emphasized immuno-oncology, targeted therapy, and proprietary bio-conjugate technologies intended to direct therapeutic activity toward tumors displaying elevated levels of carcinoembryonic antigen-related cell adhesion molecule 6, commonly abbreviated as CEACAM6. The present company was established on July 31, 1995, through the merger of Intercon Pharma Inc. and International Helix Biotechnologies Inc. Its corporate lineage therefore reaches back to Intercon Pharma, which was founded in 1988. Following the 1995 merger, Helix BioPharma was listed on the Toronto Stock Exchange. It has subsequently also been quoted in the United States on the OTC Pink Market and in Germany on the Frankfurt Stock Exchange. During its earlier development, the company investigated more than one therapeutic area, including a gastrointestinal product. Over time, it concentrated its resources on oncology and built a research portfolio around therapies intended to address prevalent or treatment-resistant cancers. Helix has obtained multiple United States patents relating to its proprietary technologies, supporting the development of its candidate programs and associated delivery or targeting approaches. Helix operates primarily as a research and development organization rather than as a large commercial pharmaceutical manufacturer. Its activities center on scientific discovery, preclinical work, clinical testing, licensing or acquisition of oncology assets, and collaboration with external biotechnology and research organizations. The company has pursued both antibody-based and cell-based approaches. In 2018, it entered an agreement with ProMab Biotechnologies to explore chimeric antigen receptor T-cell therapies for hematological malignancies. It has also worked with institutions including the H. Lee Moffitt Cancer Center & Research Institute. In 2025, Helix expanded its development pipeline by acquiring two oncology candidates from the Laevoroc Group: LEUMUNATM and GEMCEDATM. The transaction added programs to a portfolio already centered on targeted cancer treatment and reflects the company’s use of external transactions alongside internal research. Its development activities have taken place against operational challenges affecting biotechnology companies, including the COVID-19 pandemic and supply-chain pressures associated with geopolitical disruption following the war in Ukraine. Publicly available descriptions characterize Helix as an oncology-focused development company whose value proposition depends on advancing proprietary candidates toward clinical validation and, ultimately, potential commercialization.

Helix BioPharma Corp. traces its corporate origins to Intercon Pharma Inc., founded in 1988. The company that is now known as Helix BioPharma was created on July 31, 1995, when Intercon Pharma merged with International Helix Biotechnologies Inc. The newly formed business adopted the Helix BioPharma name and became listed on the Toronto Stock Exchange. This 1995 transaction marks the establishment of the present corporate entity, while 1988 represents the beginning of one of its predecessor organizations. In its early period, Helix investigated several therapeutic possibilities, including a gastrointestinal product. The company later redirected its principal research effort toward oncology, a specialization that became central to its corporate identity and development strategy. Its work has focused on treatments for cancers that are widespread, difficult to manage, or insufficiently addressed by existing therapies. The company’s technical interests have included targeted drug delivery, immuno-oncology, and therapies directed at biological characteristics of tumors. A significant part of Helix’s research platform has involved bio-conjugates designed to target tumors that overexpress CEACAM6. This approach seeks to connect therapeutic activity with a tumor-associated molecular feature, potentially concentrating treatment in relevant cancer cells. Helix has received several United States patents covering proprietary technologies connected with its development work. These patents form part of the company’s effort to establish differentiated scientific assets in a competitive oncology field. Helix has also used partnerships to extend its research capabilities. In 2018, the company entered a collaboration with ProMab Biotechnologies to explore CAR-T therapies for hematological malignancies. Its research portfolio has additionally included relationships with organizations such as the H. Lee Moffitt Cancer Center & Research Institute. These collaborations reflect a development model that combines internal programs with external scientific and biotechnology expertise. The company’s operations have been affected by broader conditions facing the biotechnology sector. The COVID-19 pandemic created operational disruption, while supply-chain difficulties linked to geopolitical events, including the war in Ukraine, created additional challenges for research and development activities. These pressures occurred while Helix continued to pursue early-stage oncology programs. In 2025, Helix broadened its pipeline through the purchase of LEUMUNATM and GEMCEDATM from the Laevoroc Group. The acquisition added two oncology candidates to its existing portfolio and illustrated the company’s willingness to supplement proprietary discovery with externally developed assets. Helix remains a publicly traded Canadian biopharmaceutical developer, quoted on the Toronto Stock Exchange under HBP and also traded on the OTC Pink Market and Frankfurt Stock Exchange. Its business remains centered on advancing oncology candidates through research and early clinical development rather than on a broad portfolio of established commercial medicines.

• 2025

  Pipeline expansion through candidate acquisitions

  [1]Helix BioPharma Corp.en.wikipedia.org

  Helix acquires the oncology candidates LEUMUNATM and GEMCEDATM from the Laevoroc Group.

• 2018

  CAR-T research collaboration

  [1]Helix BioPharma Corp.en.wikipedia.org

  Helix enters an agreement with ProMab Biotechnologies to investigate CAR-T therapies for hematological malignancies.

• 1995

  Helix BioPharma is established

  [1]Helix BioPharma Corp.en.wikipedia.org

  Intercon Pharma Inc. merges with International Helix Biotechnologies Inc. on July 31, creating Helix BioPharma Corp.

• 1995

  Toronto Stock Exchange listing

  [1]Helix BioPharma Corp.en.wikipedia.org

  The newly formed Helix BioPharma is listed on the Toronto Stock Exchange.

• 1988

  Intercon Pharma is founded

  [1]Helix BioPharma Corp.en.wikipedia.org

  Intercon Pharma Inc., one of the predecessor organizations of Helix BioPharma, is established.

A publicly traded, oncology-focused biotechnology developer pursuing targeted and immune-based therapies for solid tumors and hematological malignancies, with an emphasis on proprietary bio-conjugate technology and externally sourced development candidates.

• Targeted oncology platform

  CEACAM6-targeted bio-conjugate platform

  Helix’s proprietary bio-conjugate research platform is intended to address tumors that overexpress CEACAM6, a carcinoembryonic antigen-related cell adhesion molecule. The platform is part of the company’s effort to develop targeted cancer therapies that link therapeutic action to a tumor-associated biological marker. Public descriptions identify it as a central component of Helix’s oncology research and development activities.

• Oncology drug candidate · 2025

  LEUMUNATM

  LEUMUNATM is an oncology candidate acquired by Helix BioPharma from the Laevoroc Group in 2025. The acquisition expanded Helix’s development pipeline. The available reference material identifies it as a cancer-focused development asset but does not provide sufficient detail to characterize its mechanism, clinical stage, target indication, or regulatory status.

• Oncology drug candidate · 2025

  GEMCEDATM

  GEMCEDATM is an oncology candidate purchased by Helix BioPharma from the Laevoroc Group in 2025. It became part of Helix’s expanded cancer pipeline through that transaction. The supplied reference material does not establish the candidate’s detailed pharmacology, development phase, intended patient population, or regulatory position.

• Cell therapy research · 2018

  CAR-T therapy research programs

  Through its 2018 collaboration with ProMab Biotechnologies, Helix explored chimeric antigen receptor T-cell approaches for different hematological malignancies. These activities represent a research and development collaboration rather than a confirmed commercial product, and the available material does not specify a marketed CAR-T therapy or late-stage program.

• 2025

  Acquisition of two oncology candidatesM&A

  Background

  Helix aimed to enlarge its oncology development pipeline through externally sourced assets.

  Action taken

  The company purchased LEUMUNATM and GEMCEDATM from the Laevoroc Group.

  Aftermath

  The transaction increased the number of oncology candidates in Helix’s pipeline. No transaction value or subsequent clinical outcome is provided in the reference material.

  Source

• 2018

  Expansion into collaborative CAR-T researchStrategy

  Background

  Helix sought to broaden its oncology research beyond its proprietary targeted-therapy work and explore cell-based treatment approaches.

  Action taken

  The company entered a collaboration with ProMab Biotechnologies covering CAR-T therapies for different hematological malignancies.

  Aftermath

  The agreement added a cell-therapy research component to Helix’s oncology portfolio; the supplied material does not document a commercial product resulting from the collaboration.

  Source

• 1995

  Formation of the present company through mergerStrategy

  Background

  Intercon Pharma Inc. and International Helix Biotechnologies Inc. combined to establish the present Helix BioPharma corporate entity.

  Action taken

  The merged company was established on July 31, 1995, and subsequently listed on the Toronto Stock Exchange.

  Aftermath

  The merger created the corporate platform that later concentrated its principal activities on oncology drug research and development.

  Source

• 2022.03.22

  Reported2022.03.22

  Helix BioPharma announces CFO's planned departure[2]Helix BioPharma宣布首席财务官计划离任finanznachrichten.de

  Helix BioPharma announced that CFO Frank Michalargias intends to resign from his position, effective no later than May 15, 2022, to pursue a new employment opportunity.

• 2020.12.30

  Reported2020.12.30

  Helix BioPharma closes private placement[3]Helix BioPharma完成私募融资finanznachrichten.de

  Helix BioPharma announced that it had closed a private placement financing for gross proceeds of $3,000,000. The company said it intended to use the net proceeds for working capital and research and development activities.

• 2020.12.04

  Reported2020.12.05

  Helix BioPharma closes private placement[4]Helix BioPharma完成私募融资finanznachrichten.de

  Helix BioPharma announced that it closed a private placement financing for gross proceeds of $1,100,000. It said it intended to use the net proceeds for working capital and research and development activities.

Read more

1. 1Helix BioPharma Corp.en.wikipedia.org
2. 2Helix BioPharma宣布首席财务官计划离任finanznachrichten.de
3. 3Helix BioPharma完成私募融资finanznachrichten.de
4. 4Helix BioPharma完成私募融资finanznachrichten.de
5. 5Helix BioPharma Corp.: Helix Biopharma Corp. Closes Private Placement and Announces Early Warrant Exercise Incentive Program and Extension of Warrant Exercise Periodfinanznachrichten.de